Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit
Plaintiff Lawyers: Ranbaxy ‘Facing Liabilities In The Billions’
A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.
You may also be interested in...
Sun Pharma’s key antitrust trial kicks off and Lannett awaits word from the US FDA for its generic Advair filing during a busy first month of 2022, which also features updates from the annual J.P. Morgan Health Care Conference.
But court finds FDA has authority to correct its mistakes and revoke Ranbaxy’s tentative ANDA approvals
Ranbaxy Laboratories is free to launch its generic version of the Novartis drug Diovan (valsartan) for treating high blood pressure in the U.S. after gaining U.S. FDA approval.